Oxford BioMedica Announces US$3 million Option Exercise Payment from Sanofi
— Sanofi acquires exclusive worldwide rights to develop and commercialise StarGen™ and UshStat® — Oxford, UK – 29 June… Read More
Oxford BioMedica Announces Proposed Firm Placing of £11 million and Open Offer of up to £5 million
Click here to read the full announcement THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT… Read More
Oxford BioMedica Announces Successful MHRA Inspection for its Proprietary Manufacturing Facility
— MHRA approval received to enable GMP manufacturing for clinical supply — Oxford, UK – 8 June 2012: Oxford BioMedica plc (“Oxford BioMedica”… Read More
Oxford BioMedica Interim Management Statement May 2012
Oxford, UK – 11 May 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: Oxford Biomedica), the leading gene-based biopharmaceutical company, today publishes its interim management statement for the period from 1 January to 10 May 2012. Read More
Oxford BioMedica Announces Successful Completion of ProSavin® Phase I/II Study in Parkinson’s Disease
— Study meets primary endpoint: ProSavin® is safe, well-tolerated and mediates long-term improvement of motor function — Oxford, UK – 16 April 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”)… Read More
Oxford BioMedica Announces Successful Completion of ProSavin® Phase I/II Study in Parkinson’s Disease
— Study meets primary endpoint: ProSavin® is safe, well-tolerated and mediates long-term improvement of motor function — Oxford, UK – 16 April 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”)… Read More
Oxford BioMedica Plc Preliminary Results for the Year Ended 31 December 2011
Click here to download the full 2011 preliminary results statement.Click here to download the 2011 results slide deck.Click here to listen to the… Read More
Oxford BioMedica plc Management and Board change
—Appointment of new Chief Financial Officer and Company Secretary — Oxford, UK – 10 February 2012: Oxford BioMedica (“Oxford BioMedica” or… Read More
Oxford BioMedica Announces Interim Update on ProSavin® Phase I/II Study in Parkinson’s Disease
— Positive review of all patient cohorts by Data Monitoring Committee —— ProSavin® provides long-term improvement of motor function —… Read More
Oxford BioMedica Interim Management Statement November 2011
Oxford, UK – 16 November 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: Oxford Biomedica), the leading gene-based biopharmaceutical company, today publishes its interim management statement for the period from 1 July to 15 November 2011. Read More
Oxford BioMedica Announces Research and Development Collaboration for Glaucoma
— Research and development agreement signed with Mayo Clinic — Oxford, UK – 31 October 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the… Read More
Oxford BioMedica Announces US IND Approval for Novel Ocular Product in Usher Syndrome Type 1B
— Third ocular product partnered with Sanofi approved to enter clinical development — Oxford, UK – 18 October 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: Oxford Biomedica),… Read More